Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 164.91 Billion KRW | 69.24% |
| 2022 | 85.12 Billion KRW | 41.33% |
| 2021 | 69.07 Billion KRW | 12.38% |
| 2020 | 62.93 Billion KRW | -28.09% |
| 2019 | 72.05 Billion KRW | 2.56% |
| 2018 | 58.95 Billion KRW | -5.16% |
| 2017 | 83.19 Billion KRW | 42.44% |
| 2016 | 59 Billion KRW | -18.26% |
| 2015 | 73.12 Billion KRW | 2.07% |
| 2014 | 67.13 Billion KRW | -24.42% |
| 2013 | 89.54 Billion KRW | 54.81% |
| 2012 | 60.41 Billion KRW | -29.04% |
| 2011 | 83.31 Billion KRW | 10.62% |
| 2010 | 81.12 Billion KRW | -29.54% |
| 2009 | 90.66 Billion KRW | 183.8% |
| 2008 | 60.92 Billion KRW | -54.34% |
| 2007 | 87.42 Billion KRW | 12.05% |
| 2006 | 78.83 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 41.19 Billion KRW | -52.77% |
| 2024 Q2 | 54.51 Billion KRW | 43.56% |
| 2023 FY | - KRW | 69.24% |
| 2023 Q1 | 158.98 Billion KRW | 1430.17% |
| 2023 Q4 | 40.18 Billion KRW | -75.63% |
| 2023 Q3 | 164.87 Billion KRW | -9.96% |
| 2023 Q2 | 183.11 Billion KRW | 15.18% |
| 2022 Q3 | 39.99 Billion KRW | 0.58% |
| 2022 Q4 | -11.95 Billion KRW | -129.88% |
| 2022 FY | - KRW | 41.33% |
| 2022 Q2 | 39.76 Billion KRW | 24.73% |
| 2022 Q1 | 31.88 Billion KRW | -5.64% |
| 2021 Q3 | 32.91 Billion KRW | 13.61% |
| 2021 Q1 | -23.75 Billion KRW | -190.01% |
| 2021 Q2 | 28.97 Billion KRW | 221.97% |
| 2021 Q4 | 33.78 Billion KRW | 2.65% |
| 2021 FY | - KRW | 12.38% |
| 2020 Q4 | 26.39 Billion KRW | 63.03% |
| 2020 Q1 | 16.85 Billion KRW | 223.48% |
| 2020 FY | - KRW | -28.09% |
| 2020 Q3 | 16.18 Billion KRW | 134.66% |
| 2020 Q2 | 6.89 Billion KRW | -59.08% |
| 2019 FY | - KRW | 2.56% |
| 2019 Q1 | 23.27 Billion KRW | 49.0% |
| 2019 Q3 | 16.21 Billion KRW | -50.3% |
| 2019 Q4 | 5.21 Billion KRW | -67.87% |
| 2019 Q2 | 32.62 Billion KRW | 40.19% |
| 2018 Q3 | 21.67 Billion KRW | -16.23% |
| 2018 FY | - KRW | -5.16% |
| 2018 Q1 | 19.4 Billion KRW | -7.11% |
| 2018 Q2 | 25.87 Billion KRW | 33.31% |
| 2018 Q4 | 15.62 Billion KRW | -27.93% |
| 2017 Q1 | 12.8 Billion KRW | -41.56% |
| 2017 FY | - KRW | 42.44% |
| 2017 Q4 | 20.89 Billion KRW | -18.9% |
| 2017 Q3 | 25.75 Billion KRW | -5.68% |
| 2017 Q2 | 27.31 Billion KRW | 113.22% |
| 2016 FY | - KRW | -18.26% |
| 2016 Q1 | 12.52 Billion KRW | 3.28% |
| 2016 Q4 | 21.91 Billion KRW | 73.49% |
| 2016 Q3 | 12.63 Billion KRW | -10.31% |
| 2016 Q2 | 14.08 Billion KRW | 12.41% |
| 2015 FY | - KRW | 2.07% |
| 2015 Q1 | 20.64 Billion KRW | 73.8% |
| 2015 Q2 | 22.68 Billion KRW | 9.89% |
| 2015 Q3 | 19.35 Billion KRW | -14.7% |
| 2015 Q4 | 12.13 Billion KRW | -37.31% |
| 2014 Q1 | 20.35 Billion KRW | 23.43% |
| 2014 FY | - KRW | -24.42% |
| 2014 Q3 | 17.95 Billion KRW | -22.31% |
| 2014 Q4 | 11.88 Billion KRW | -33.84% |
| 2014 Q2 | 23.11 Billion KRW | 13.55% |
| 2013 Q2 | 26.97 Billion KRW | 29.41% |
| 2013 Q1 | 20.84 Billion KRW | -0.78% |
| 2013 FY | - KRW | 54.81% |
| 2013 Q4 | 16.49 Billion KRW | -43.93% |
| 2013 Q3 | 29.41 Billion KRW | 9.02% |
| 2012 FY | - KRW | -29.04% |
| 2012 Q1 | 17.5 Billion KRW | 0.0% |
| 2012 Q2 | 6.31 Billion KRW | -63.91% |
| 2012 Q3 | 19.23 Billion KRW | 204.46% |
| 2012 Q4 | 21.01 Billion KRW | 9.24% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | - KRW | 10.62% |
| 2011 Q3 | 26.02 Billion KRW | -1.22% |
| 2011 Q2 | 26.34 Billion KRW | -10.48% |
| 2011 Q1 | 29.42 Billion KRW | 0.0% |
| 2010 Q2 | 24.24 Billion KRW | -32.45% |
| 2010 FY | - KRW | -29.54% |
| 2010 Q3 | 31.91 Billion KRW | 31.66% |
| 2010 Q1 | 35.88 Billion KRW | 26.21% |
| 2009 Q4 | 28.43 Billion KRW | 1.44% |
| 2009 FY | - KRW | 183.8% |
| 2009 Q3 | 28.03 Billion KRW | 33.96% |
| 2009 Q2 | 20.92 Billion KRW | 0.0% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 FY | - KRW | -54.34% |
| 2008 Q3 | 7.1 Billion KRW | -59.89% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 Q2 | 17.71 Billion KRW | 0.0% |
| 2008 Q4 | 8.84 Billion KRW | 24.48% |
| 2007 Q2 | 20.16 Billion KRW | 0.0% |
| 2007 FY | - KRW | 12.05% |
| 2007 Q4 | 23.79 Billion KRW | -7.54% |
| 2007 Q3 | 25.73 Billion KRW | 27.63% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -3294.428% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | -16.658% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 357.531% |
| HANDOK Inc. | 35.06 Billion KRW | -370.283% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 16009.385% |
| Yuhan Corporation | 127.43 Billion KRW | -29.411% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -339.52% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 860.403% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 48.996% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -3204.65% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -990.819% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -4720.635% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -3543.352% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -364.721% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -3294.428% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 992.78% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -2415.845% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 434.564% |
| JW Holdings Corporation | 187.88 Billion KRW | 12.227% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 421.916% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 41.856% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -84.837% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 544.906% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -1148.431% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -1294.273% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -784.021% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -3294.428% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -199.988% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -84.837% |
| Yuhan Corporation | 127.43 Billion KRW | -29.411% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -392.631% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -2055.769% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -114.093% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -84.837% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -350.157% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -132.992% |
| CKD Bio Corp. | -1.63 Billion KRW | 10214.593% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -231.197% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -406.466% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -348.006% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 544.906% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -164.774% |
| Boryung Corporation | 114.28 Billion KRW | -44.296% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 639.49% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -990.819% |
| JW Lifescience Corporation | 50.82 Billion KRW | -224.445% |